GlassScriptPhysician profile
Lucy Joseph
NPI 1720697188
$5,910.04
in general payments reported to CMS, 2019-2025
42 companies · $2,894 in 2025
The $2,894 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $446 · 2022: $131 · 2023: $501 · 2024: $1,938 · 2025: $2,894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,980 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $1,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,980.39 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $1,073.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,606.75 | 2023-2025 | |
| Daiichi Sankyo INC. | $452.69 | 2024-2025 | Enhertu |
| Incyte Corporation | $346.57 | 2021-2025 | Jakafi |
| Seagen INC. | $328.35 | 2021-2025 | Tukysa, Adcetris |
| Gilead Sciences, INC. | $317.54 | 2023-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $295.71 | 2024-2025 | Opdivo |
| Abbvie INC. | $259.52 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $257.31 | 2021-2025 | Evusheld, Imfinzi, Tagrisso |
| Glaxosmithkline, LLC. | $194.80 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Taiho Oncology, INC. | $188.96 | 2023-2025 | |
| Astellas Pharma US INC | $159.86 | 2023-2025 | Padcev, Xtandi, Xospata |
| Janssen Biotech, INC. | $155.89 | 2021-2025 | Erleada, Tecvayli, Balversa |
| Merck Sharp & Dohme LLC | $141.90 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Eisai INC. | $141.00 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $130.63 | 2023-2025 | Vpriv, Alunbrig, Ninlaro |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucy Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.